Overview
May 12, 2007
Baltimore, MD
is intended to facilitate interaction among oncologists, radiation oncologist and researchers interested in development of novel therapeutics for treatment of lung cancer. In addition to multimodality therapy, adjuvant therapy and surgery, this symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer. There will be in-depth discussion of both antiangiogenic agents and inhibitors of EGFR pathways. Drugs that target multiple signaling pathways will also be given significant focus.
Target Audience
This symposium is directed primarily to medical oncologists, radiation oncologists and researchers interested in new developments for treatment of lung cancer. No specific skill or knowledge other than a basic training in oncology are required for successful participation in this activity. Fellows, nurses and pharmacists are also invited to attend.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the current status of chemotherapy, radiation therapy, and state-of-the-art therapies of lung cancer
- Define the current status of radiation therapy and multimodality therapy in the treatment of localized and advance lung cancer
- Outline the clinical data supporting the use of EGFR inhibitors in the treatment of lung cancer
- Review agents that target angiogenesis, including the safety profile and efficacy
- Specify the impact of multi-targeted kinase inhibitors in the management of lung cancer
- Describe novel therapeutic agents that potentially improve upon standard chemotherapeutics
- Define the importance of supportive care in the management of lung cancer
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Lung Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.